These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 19469803

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 4. Which oral agent to use when metformin is no longer effective?
    Bannon M.
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 6. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 7. What to add in with metformin in type 2 diabetes?
    Petrie JR, Adler A, Vella S.
    QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
    [Abstract] [Full Text] [Related]

  • 8. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract] [Full Text] [Related]

  • 9. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE.
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract] [Full Text] [Related]

  • 10. Thiazolidinedione derivatives in type 2 diabetes mellitus.
    Tack CJ, Smits P.
    Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M.
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J.
    Curr Med Res Opin; 2006 Mar; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [Abstract] [Full Text] [Related]

  • 19. Diabetes under control: Understanding oral antidiabetic agents.
    Longo R.
    Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.